1
Clinical Trials associated with Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine(Zhifei Longcom Biopharmaceutical)Anhui Zhifei Longcom Biologic Pharmacy co. Ltd.
The study was designed as a randomized, blind and controlled trial. A total of 300 patients aged 18 and above who were immunized with recombinant novel coronavirus protein vaccine (CHO cell) for more than 4 months (60 patients aged 60 and above) were randomly and blind divided into the experimental group and the control group, and received the experimental vaccine and the control vaccine, respectively.
In addition, 100 patients over 4 months after the completion of basic immunization with COVID-19 mRNA vaccine were selected as the open observation group, all of whom received 1 dose of experimental vaccine.
100 Clinical Results associated with Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine(Zhifei Longcom Biopharmaceutical)
100 Translational Medicine associated with Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine(Zhifei Longcom Biopharmaceutical)
100 Patents (Medical) associated with Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine(Zhifei Longcom Biopharmaceutical)
100 Deals associated with Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine(Zhifei Longcom Biopharmaceutical)